This study is testing a combination of two drugs, LP-168 and Obinutuzumab, for people with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). You might be able to join if you are 18 or older and have CLL or SLL that needs treatment. The study aims to see if this combination is safe and effective in helping people achieve a complete remission (when signs of cancer disappear). Researchers will look at how many people reach complete remission after 12 months. This study is for people who have already been treated for CLL/SLL, or who have a specific genetic change called a BTK T474I mutation. There are 34 people expected to join this study.

Study design

This is a Phase 2 study with two groups of participants, testing the combination of LP-168 and Obinutuzumab. It aims to enroll 34 participants.

What's involved

You would receive LP-168 daily for 12 cycles. Starting in cycle 7, you would also receive Obinutuzumab for 6 cycles, for a minimum of 12 cycles of therapy.

Compensation

Not stated in the trial record.

Follow-up

The primary goal of the study is measured at 12 months, looking at complete remission.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.